Assignee
CELCUITY INC
US·7 granted patents·4 pending applications·12 citations·filing 2016–2025
Top patents by PatentIndex Score
11 records- 0188US11333659B2Methods of measuring signaling pathway activity for selection of therapeutic agentsCELCUITY INC·Filed 2018·Granted May 17, 2022·3 cites·16 claims
- 0288US11073509B2Assays and methods for determining the responsiveness of an individual subject to a therapeutic agentCELCUITY INC·Filed 2016·Granted Jul 27, 2021·5 cites·7 claims
- 0387US10976307B2Whole cell assays and methodsCELCUITY INC·Filed 2018·Granted Apr 13, 2021·2 cites·20 claims
- 0481US11591573B2Methods of preparing a primary cell sampleCELCUITY INC·Filed 2018·Granted Feb 28, 2023·2 cites·10 claims
- 0574US12215356B2Methods of preparing a primary cell sampleCELCUITY INC·Filed 2023·Granted Feb 4, 2025·0 cites·10 claims
- 0674US2021215673A1Whole cell assays and methodsCELCUITY INC·Filed 2021·Application pending·0 cites
- 0772US12320799B2Methods of measuring signaling pathway activity for selection of therapeutic agentsCELCUITY INC·Filed 2022·Granted Jun 3, 2025·0 cites·11 claims
- 0870US12350276B2Methods for the treatment of cancer using 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]ureaCELCUITY INC·Filed 2022·Granted Jul 8, 2025·0 cites·29 claims
- 0968US2025345342A1Methods for the treatment of cancer using 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]ureaCELCUITY INC·Filed 2025·Application pending·0 cites
- 1059US2026053814A1Treatment regimens for gedatolisib in hormonally-driven disordersCELCUITY INC·Filed 2025·Application pending·0 cites
- 1158US2022412957A1Methods of treating cancer patients with ras node or rtk targeted therapeutic agentsCELCUITY INC·Filed 2022·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →